• High quality research, facilities and equipment
• Fast set-up and approval times
• Sponsor can claim R&D cash refund

Click for more

• Very large, homogenous population
• Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
• Largest clinical trial hub in Asia, with over 17,000 active investigators

Click for more

• Large treatment-naïve population
• High disease population load
• The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
• About 1,800 investigators have participated on a minimum of 5 studies

Click for more

• Multiethnic Asian population
• Streamlined regulatory system and Strong govt. support 
• Quick start-up timelines
• Low patient costs and IRB fees

Click for more

• High-quality research, facilities and equipment
• Fast set-up and approval times
• Sponsor can claim R&D cash refund

Click for more

• Large treatment-naïve population
• Low costs
• Overall good level of English

Click for more

• Multiethnic Asian population 
• Regional clinical research hub
• Efficient regulatory process and good infrastructure

Click for more

• Homogenous and concentrated population 
• High quality medical services and excellent infrastructure
• The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018

Click for more

• Large homogenous population 
• High prevalence of communicable diseases
• Efficient regulatory system
• Low operational cost

Click for more

• Following the acquisition and integration of a long standing full-service CRO partner, Novotech now provides services across the United States"

Click for more